Clinical Implication of Sequential Circulating Tumor DNA Assessments for the Treatment of Diffuse Large B-Cell Lymphoma
These findings support the clinical utility of ctDNA for dynamic risk assessment in DLBCL, and suggest that integrating ctDNA with imaging biomarkers may guide more personalized therapeutic strategies. Further validation using highly sensitive ctDNA assays is warranted to optimize its role in routine clinical practice.
Authors
- Sunghoon Jung (ORCID: https://orcid.org/0000-0001-6086-0326)
- Je-Jung Lee (ORCID: https://orcid.org/0000-0003-1939-4364)
- Ga‐Young Song (ORCID: https://orcid.org/0000-0002-5203-2982)
- Deok‐Hwan Yang (ORCID: https://orcid.org/0000-0002-8167-8520)
- Seo‐Yeon Ahn (ORCID: https://orcid.org/0000-0002-6061-1490)
- Minuk Son (ORCID: https://orcid.org/0009-0002-1499-6876)
- Younmu Jung
- Sae‐Ryung Kang (ORCID: https://orcid.org/0000-0003-0172-5508)
- Seung Jung Han (ORCID: https://orcid.org/0000-0002-4038-6118)
- Hyeoung‐Joon Kim (ORCID: https://orcid.org/0000-0002-0998-1090)
- Joo-Heon Park (ORCID: https://orcid.org/0000-0002-6842-0234)
- Mihee Kim (ORCID: https://orcid.org/0000-0001-7781-8183)
- Jae-Sook Ahn
- Ho Cheol Jang (ORCID: https://orcid.org/0009-0000-1155-2298)
Institutions
- Chonnam National University Hwasun Hospital (KR)
Publication Details
- Journal
- Cancers
- Published
- 2025-05-22
- DOI
- https://doi.org/10.3390/cancers17111734
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Chonnam National University
- Korea Health Industry Development Institute